Characterization of Pain in Lipedema: Reliability and Validity of Pain Pressure Thresholds and Hand-Held Sphygmomanometer Assessments in People with Lipedema
Lymphatic Research and Biology · 01.04.2025 · 23 (2) · 95-100
DOI: 10.1089/lrb.2024.0058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lymphatic Research and Biology, online erschienen am 10.04.2025. Verfasst von Francesco Bettariga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Australia. Hauptthemen laut MEDLINE: Lipedema, Pain Measurement, Pain Threshold, Sphygmomanometers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Lipedema is a chronic condition characterized by abnormal deposition of subcutaneous adipose tissue, leading to pain. The lack of internationally recognized diagnostic criteria complicates the characterization of pain. Physiological parameters such as pain pressure threshold (PPT) represent promising prognostic markers for diagnosing lipedema, yet they remain understudied. This study aimed to evaluate the reliability and validity of two pain pressure measurements, PPT and the hand-held sphygmomanometer (HHS) in lipedema.
Methods
A total of 28 adult females diagnosed with lipedema were recruited. Both PPT, using a digital algometer, and HHS, using a manual aneroid HHS, were performed to assess pain in the lower limbs. The testing was performed in a standing position with PPT and HHS placed on the calf. Intraclass correlation coefficient (ICC) and coefficient of variation (CV) were employed to assess the within session reliability, while the validity between PPT and HHS was analyzed using R 2 in a linear regression model.
Results
The results showed excellent reliability for both PPT and HHS, with ICC indicating high consistency (ICC = 0.93 to 0.97) and CV showing acceptable scores (CV = 3.62% to 9.06%). In addition, good validity between PPT and HHS was also observed ( R 2 = 0.69 to 0.74), suggesting that HHS can be a reliable alternative to PPT for pain assessment in lipedema.
Conclusion
These findings have important clinical implications, as they expand the knowledge of pain characterization in people with lipedema, potentially aiding in diagnostic refinement. In addition, a cost-effective and accessible method for assessing pain was examined (i.e., HHS), showing promising findings and providing an objective method to help diagnose lipedema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Australia.
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.
- StudioErre, Brescia, Italy.
- Studio Fision, Giussano, Italy.
- Studio Medico Specialistico "Bellaria", Bologna, Italy.
- London Sport Institute, School of Science and Technology, Middlesex University, London, United Kingdom.
ORCID-Profile: Francesco Bettariga
Zitieren
APA
Bettariga, F., Fumagalli, L., Aloisi, D., Maestroni, L., & Mantovani, S. (2025). Characterization of Pain in Lipedema: Reliability and Validity of Pain Pressure Thresholds and Hand-Held Sphygmomanometer Assessments in People with Lipedema. Lymphatic Research and Biology, 23(2), 95-100. https://doi.org/10.1089/lrb.2024.0058
Vancouver
Bettariga F, Fumagalli L, Aloisi D, Maestroni L, Mantovani S. Characterization of Pain in Lipedema: Reliability and Validity of Pain Pressure Thresholds and Hand-Held Sphygmomanometer Assessments in People with Lipedema. Lymphatic Research and Biology. 2025;23(2):95-100. doi:10.1089/lrb.2024.0058
BibTeX
@article{Bettariga2025,
author = {Bettariga, Francesco and Fumagalli, Luca and Aloisi, Daniele and Maestroni, Luca and Mantovani, Sara},
title = {Characterization of Pain in Lipedema: Reliability and Validity of Pain Pressure Thresholds and Hand-Held Sphygmomanometer Assessments in People with Lipedema},
journal = {Lymphatic Research and Biology},
year = {2025},
volume = {23},
number = {2},
pages = {95--100},
doi = {10.1089/lrb.2024.0058}
}
EUVIMED